Neural stem cell therapy - TheraBiologics

Drug Profile

Neural stem cell therapy - TheraBiologics

Alternative Names: HB1.F3.CD neural stem cells; TBio-01; TBX-01; TBX.CD + 5-FC; TBX.CE + irinotecan; TBX.CE NSCs + IRN SN-38

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraBiologics
  • Developer City of Hope National Medical Center; TheraBiologics
  • Class Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Glioma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Late-stage disease) in USA (Intracerebral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top